CytomX CX-904 Shows Promise in Pancreatic Cancer, Achieves $10M Milestones

May 8, 2024, 08:36 PM

CytomX Therapeutics announced positive initial Phase 1a dose escalation data for its monotherapy CX-904, an EGFRxCD3 PROBODY T-cell engager. The study reported measurable tumor reductions in eight patients, including two of six efficacy-evaluable pancreatic cancer patients who achieved confirmed partial responses per RECIST 1.1. All six pancreatic cancer patients reached disease control. Despite this, the results in other cancers like CRC, NSCLC, gastric, and HNSCC were less promising, with only partial responses observed in pancreatic cancer. The company's stock experienced significant volatility, surging 83% after hours following the announcement. CytomX has partnered with Amgen and achieved $10 million of milestones under a T-cell engaging bispecific collaboration with Astellas for preclinical progress on the first two programs. Further updates are expected by the end of 2024.